Goldman's 'Buyback' Basket: CMCSA, GM, MPC, Etc
Goldman's High Growth Investment Ratio Stocks: EA, AMZN, FANG, Etc
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80
Incyte (INCY) Gets a Buy From TD Cowen
Possible Bearish Signals With Incyte Insiders Disposing Stock
Express News | Incyte Announces Health Canada Approval of Opzelura (Ruxolitinib) Cream for Treatment of Atopic Dermatitis (Ad) and Nonsegmental Vitiligo
Incyte Announces Health Canada Approval of OPZELURA (Ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD) and Nonsegmental Vitiligo
What to Expect From Incyte's Next Quarterly Earnings Report
Express News | Knight Therapeutics Announces Approval of Minjuvi® (Tafasitamab) in Mexico
Knight Therapeutics Announces Approval of Minjuvi (Tafasitamab) in Mexico
Innate Pharma Names Jonathan Dickinson as New CEO, Chairman
A Look Into Incyte Inc's Price Over Earnings
Wells Fargo Sticks to Their Hold Rating for Incyte (INCY)
Express News | Incyte Corporation : Wells Fargo Cuts Target Price to $62 From $63
Press Release: Incyte to Report Third Quarter Financial Results
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Guggenheim Adjusts Price Target on Incyte to $86 From $92
Wolfe Research Initiates Incyte(INCY.US) With Buy Rating, Announces Target Price $84
Optimism Around Aquestive As It Moves Forward With Severe Allergy, Baldness Candidate
Is Incyte Stock Underperforming the Nasdaq?